Search Results

VenoStent, Inc. announced that it closed an additional $4 million from Norwest Venture Partners to round out its Series A financing at $20 million with Good Growth Capital and IAG Capital Partners co-leading the deal.

Biolinq Incorporated announced the completion of $58 million in financing led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical.

Sofinnova Partners announced that Dr. Joshua Makower, co-founder and director of the Stanford Byers Center for Biodesign, has joined Sofinnova as an advisory Venture Partner.

RiverVest Venture Partners, a leading venture capital firm, announced today the closing of its RiverVest Venture Fund V, L.P. (“Fund V”), with $275 million of capital commitments in an oversubscribed fundraise.

With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.